Retatrutide is a once-weekly injection therapy that activates three metabolic receptors: GLP-1, GIP, and glucagon. This triple-hormone mechanism suppresses appetite (GLP-1), increases satiety and metabolic efficiency (GIP), and accelerates fat oxidation (glucagon). The combined effect produces sustained weight loss of 24–28% in clinical trials—significantly higher than single-hormone therapies like semaglutide or dual-agonist tirzepatide. Retatrutide works by resetting hunger signals and increasing your baseline metabolic rate, making it easier to eat less without constant willpower.

TRIUMPH-1 clinical trial data showed average weight loss of 24.2–28.3% of baseline body weight over 48–80 weeks at the highest therapeutic dose. For a 200-pound patient, this translates to 48–56 pounds. Weight loss typically accelerates weeks 4–12 as medication reaches steady state, plateaus slightly around week 16–20, then resumes with continued dose escalation. Results vary by baseline BMI, adherence to lifestyle changes, and individual metabolism. Most LA ViE MD patients report visible changes by week 6 and significant reductions by 12 weeks. Importantly, weight loss is durable: discontinuation studies show most patients maintain 80–90% of achieved loss 6+ months after stopping.

Retatrutide is currently in final FDA review stages with anticipated approval in late 2026 or early 2027. LA ViE MD is actively monitoring regulatory timelines and accepting pre-registration for eligible California patients. Many patients currently using semaglutide or tirzepatide can transition smoothly once retatrutide becomes available. If you cannot wait, we offer physician-supervised tirzepatide weight loss as a proven dual-agonist alternative—many patients achieve 15–22% weight loss while building healthy habits and establishing care relationships with our team. Book a free consultation to discuss your options and register for retatrutide availability notifications.

Tirzepatide (Mounjaro, Zepbound) is a GLP-1/GIP dual agonist; retatrutide adds glucagon activation. Both suppress appetite and increase satiety, but retatrutide’s triple-receptor design amplifies metabolic rate and fat oxidation beyond tirzepatide’s capabilities. In head-to-head trials, retatrutide produced 24–28% weight loss versus tirzepatide’s 15–22% over comparable timeframes. Both require weekly injections and physician oversight. Tirzepatide is FDA-approved and available now; retatrutide is pending 2026–2027 approval. For California patients, tirzepatide is an excellent current option if you want immediate results, with a straightforward transition to retatrutide once approved if you desire even greater efficacy.

Common, transient side effects in TRIUMPH-1 were nausea (25–35%, typically weeks 1–2), mild vomiting (5–10%), constipation (15–20%), and appetite loss. These resolve within 2–4 weeks as your body adjusts. Serious adverse events were rare. LA ViE MD manages side effects through slow dose escalation, baseline EKG and lab work, monthly monitoring, and real-time support. Nausea improves with small frequent protein-rich meals, hydration, and ginger; constipation responds to fiber and stool softeners. Most patients tolerate full therapeutic doses comfortably by month 3–4. Severe abdominal pain or persistent vomiting requires immediate contact with our office.

Yes. Physician-led medical spa supervision offers baseline metabolic assessment, personalized dosing, real-time side effect management, and intervention if complications arise. LA ViE MD conducts complete medical histories, baseline EKG, liver/kidney/thyroid labs, and medication interaction screening—identifying contraindications that online prescribers may miss. Dr. Neetu Nebhwani, board-certified internal medicine physician, designs individualized protocols and adjusts doses based on your response. Monthly in-person visits allow vital sign monitoring and lifestyle counseling. Online prescribers typically lack this infrastructure, increasing risk of adverse outcomes, poor compliance, and inadequate metabolic improvement. Our approach ensures retatrutide works safely and effectively within your complete health context.